Medical Informer

InvestorIdeas.comEarnings Scorecard: Forest LabsZacks.comResults were hit by the loss of exclusivity on Lexapro. Excluding acquisition-related amortization, earnings came in at 78 cents. Fourth quarter revenues declined 7.3% to $1.01 billion, with net …

Read the full story

Local woman sentenced in plot to kill ex-husbandCBS42On July 23, 2009, Patterson called her own doctor's office, requested a prescription for Lexapro, a medication used to treat depression, and picked up 14 sample tablets of the drug, which she gav…

Read the full story

Lundbeck eyes new drugs as key antidepressant fadesReuters* Q1 operating profit 882 mln DKK vs forecast 925 mln * Keeps 2012 profit, revenue guidance * Says revenue grew when discounting Lexapro revenue * Shares fall 0.5 pct, underperforming European p…

Read the full story

Lundbeck keeps year outlook after Q1 lags forecastsReuters* Q1 EBIT 882 mln DKK vs average forecast 925 mln * Keeps 2012 profit, revenue guidance * Says revenue grew when discounting Lexapro revenue COPENHAGEN, May 2 (Reuters) – Danish drugmaker Lundbe…

Read the full story

Lundbeck reiterates outlook as net misses estimateMarketWatch-But Lundbeck's 2012 results will be hampered by the expiry of its patent for escitalopram in the US in March, which already resulted in a revenue decline for its antidepressant drug Lexa…

Read the full story

NORDIC STOCKS – Factors to watch on May 2Reuters| HELSINKI May 2 (Reuters) – The following stocks may be affected by newspaper reports and other factors on Wednesday: LUNDBECK The Danish drugmaker is expected to post a 29 drop in first-quarter operatin…

Read the full story

One Flabby DucklingHuffington PostI can justify it: It costs less than Lexapro, is much cheaper than all of those shrink visits. It is also something concrete I can check off my to-do list. I'm not proud to admit this, but despite my aspirations to…

Read the full story

Student Health Center pharmacy fills about 19000 prescriptions in past yearLSU The ReveilleLancon said a popular anti-depressant is the generic form of Lexapro, which is used to treat depression and anxiety that lasts more than six months, according to…

Read the full story

Zacks Reaffirms Neutral Rating on Forest Laboratories (FRX)Junction ReportZacks' analyst wrote, “Forest Labs is facing tough times with its lead product, Lexapro, losing patent protection. The company's fourth quarter earnings of $0.72 per sh…

Read the full story

The high cost of our depressionWA todayOthers in the top five most prescribed were drugs known by brand names Zoloft, Lexapro, Endep and Remeron, with Prozac number nine in a list of 21 antidepressants subsidised under the PBS. Canberrans had the secon…

Read the full story

The high cost of our depressionThe Canberra TimesOthers in the top five most prescribed were drugs known by brand names Zoloft, Lexapro, Endep and Remeron, with Prozac number nine in a list of 21 antidepressants subsidised under the PBS. Canberrans had…

Read the full story

Growing Incidence Rates, Coupled with Increasing Aging Population to Propel …San Francisco Chronicle (press release)However, pharmaceutical companies in the anxiety disorder drugs market are expected to be challenged by the need of maintaining and gr…

Read the full story

Growing Incidence Rates, Coupled with Increasing Aging Population to Propel …PR Web (press release)However, pharmaceutical companies in the anxiety disorder drugs market are expected to be challenged by the need of maintaining and growing the market …

Read the full story

Pharma & Biotech Stock Outlook – April 2012 – Industry OutlookNASDAQBesides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro and Eli Lilly's ( LLY ) Zyprexa. …

Read the full story

Mylan 1Q profit rises on Lexapro and EpiPen salesBusinessWeekGeneric drugmaker Mylan Inc. said Thursday its profit grew 24 percent in the first quarter on strong sales of the emergency allergy injection EpiPen and its generic version of the antidepress…

Read the full story